Phil, sincerely appreciate your insightful comments here. We would probably agree that Dr.M. is likely heavily involved in the details from these trials, as he should be. My guess is he and his team are capable of (Precision Medicine) Micro-Management, but in a good way.
Between now and the end of March (IMO) something WONDERFUL is going to happen. The framework for a bridge has been built using some AI/BIO indicators, AI, studies of disease history including academia. This trial execution and the data gathering process is NOT OUR FATHER'S OLDSMOBILE. This trial, these patients, the exact sequence of trials and Stage II planning is all laid out like a symphony.
So, trying to understand how the pieces fit is important. My guess is that there are no OOOPS expected in the planning. They probably already have a good read on efficacy.